my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
23-05-2012: Agilent Technologies Inc. and EQT, the Sweden-based private equity group, announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history.
“In the rapidly growing diagnostics market, Dako’s products and capabilities are a strategic complement to Agilent’s existing offerings,” said Bill Sullivan, Agilent president and chief executive officer. “Dako is one of the world’s leading providers of cancer diagnostics tools, and together we will be able to develop a wider range of products that help in the fight against cancer.”
“Agilent’s strategy in acquiring Dako is about strengthening the company’s presence in life science and about revenue growth,” said Sullivan. “Dako employs extremely talented people with specialized expertise that we highly value. Their knowledge and experience will be very important as we move forward together.”
Lars Holmkvist, CEO of Dako, said, “Our combined companies will have complementary strengths. Like Agilent, Dako has a long history as a leader in scientific advancement and a culture that values discovery and innovation. We believe that Agilent and Dako are a winning combination.”
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Agilent Technologies Inc. opened a new Customer Applications and Training Center in South Korea, showcasing its latest bio-analytical instruments. The company’s goal is to collaborate with customers to develop new applications and methodologies for research in the agriculture, environment a ... more
Agilent Technologies Secures Patent for CGH Assays
Agilent Technologies Inc. announced that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in both basic and clinical research. The U.S. patent (No. 8,232,055) has claims for measuring copy number change ... more
Agilent to Acquire Dako for $2.2 Billion
Agilent Technologies Inc. and EQT, the Sweden-based private equity group, announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history. “In ... more
Half a Century of Chromatography with Agilent and Predecessors
Twsett originated the chromatography with his work about the separation of chlorophyll in 1903. For some time it was relatively quite around this new technology. Exceptions were the workings of Kuhn and Lederer (1931) as well as of Hesse (1936 and 1942). A break through succeeded to E. Crem ... more
Agilent Technologies Sales & Services GmbH & Co. KG
Agilent T. is a global diversified technology company that serves markets that include communications, electronics and life sciences. more
Agilent to Acquire Dako for $2.2 Billion
Agilent Technologies Inc. and EQT, the Sweden-based private equity group, announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history. “In ... more
Dako Enters New Collaboration with Bristol-Myers Squibb on Pharmacodiagnostics
Dako announced it has entered into a broad framework agreement with Bristol-Myers Squibb Company on the development of pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb. ... more
As of May 9, 2011, Egil Mølsted Madsen takes over the position of Chief Financial Officer (CFO) of Dako A/S and Dako Denmark, a worldwide provider of cancer diagnostics solutions."Dako has just released its 2010 results. The best results ever in the company's history. However, our company h ... more
We contribute to improve cancer diagnostics The number of people suffering from cancer is constantly growing. A key factor in ensuring patients the best treatment is to make an accurate and full diagnosis and choose the right form of treatment at an early stage. more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
